Finally, a few studies in mice have found that the medications can reduce the buildup of the protein tau in the brain, which is a key contributor to Alzheimer’s disease. Scaling back tau buildup could ...

Wonder drugs’ like Ozempic, hailed by celebrities and some medics as a cure for an ever-mounting list of conditions, most notably obesity and diabetes, have started to appear in darker headlines ...

Among over 125,000 patients, 53.6% discontinued their GLP-1 receptor agonist by 1 year, and these rates were significantly ...

Detailed price information for Lexaria Bioscience Corp (LEXX-Q) from The Globe and Mail including charting and trades.

A recent study published in JAMA Psychiatry has uncovered promising evidence suggesting that glucagon-like peptide-1 (GLP-1) receptor agonists, particularly semaglutide and liraglutide, may be ...

Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...

Robert F. Kennedy Jr., the nominee to lead the Department of Health and Human Services, made disputed claims before the ...

Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...

Websites that sell compounded GLP-1 RAs often partially inform or misinform consumers, including with respect to US FDA approval.

A new study conducted by researchers from the University of Eastern Finland the Karolinska Institutet explored the ways that ...

KELOWNA, BC / ACCESS Newswire / January 30, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to provi ...

Detailed price information for Lexaria Bioscience Corp (LEXX-Q) from The Globe and Mail including charting and trades.